Importantly, the improvement in insulin-stimulated blood flow in the skin during empagliflozin treatment appears largely independent of changes in systemic ET-1 levels, indicating that mechanisms beyond ET-1 reduction contribute to empagliflozin’s effects on microvascular function during hyperinsulinemia. This evidence concerns the gene INS and Hyperinsulinemia.